2.82
price down icon1.40%   -0.04
after-market After Hours: 2.84 0.02 +0.71%
loading
Galectin Therapeutics Inc stock is traded at $2.82, with a volume of 65,306. It is down -1.40% in the last 24 hours and up +13.71% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$2.86
Open:
$2.84
24h Volume:
65,306
Relative Volume:
0.11
Market Cap:
$178.48M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-3.863
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
-1.05%
1M Performance:
+13.71%
6M Performance:
+129.27%
1Y Performance:
+8.88%
1-Day Range:
Value
$2.8102
$2.865
1-Week Range:
Value
$2.54
$3.18
52-Week Range:
Value
$0.726
$3.9035

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name
Name
Galectin Therapeutics Inc
Name
Phone
678-620-3186
Name
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Name
Employee
15
Name
Twitter
@galectingalt
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
GALT's Discussions on Twitter

Compare GALT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GALT
Galectin Therapeutics Inc
2.82 181.01M 0 -45.08M -33.68M -0.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-17-25 Resumed H.C. Wainwright Buy
Aug-13-20 Reiterated H.C. Wainwright Buy
Feb-13-19 Initiated B. Riley FBR Buy
Dec-07-17 Reiterated H.C. Wainwright Buy
Nov-28-17 Reiterated H.C. Wainwright Buy
Oct-19-17 Initiated ROTH Capital Buy
Mar-30-17 Upgrade H.C. Wainwright Neutral → Buy
Oct-03-16 Downgrade FBR & Co. Outperform → Mkt Perform
Sep-29-16 Downgrade H.C. Wainwright Buy → Neutral
Sep-28-16 Downgrade ROTH Capital Buy → Sell
Mar-28-16 Resumed H.C. Wainwright Buy
Sep-21-15 Initiated H.C. Wainwright Buy
Aug-01-14 Downgrade Aegis Capital Buy → Hold
Jul-30-14 Reiterated MLV & Co Buy
Jul-29-14 Reiterated MLV & Co Buy
Apr-02-14 Reiterated MLV & Co Buy
Feb-10-14 Reiterated Aegis Capital Buy
Jan-09-14 Reiterated Aegis Capital Buy
Dec-03-13 Initiated MLV & Co Buy
Aug-19-13 Reiterated Aegis Capital Buy
View All

Galectin Therapeutics Inc Stock (GALT) Latest News

pulisher
12:12 PM

Galectin Therapeutics Inc. Stock Analysis and ForecastFree Trend-Following Techniques - Autocar Professional

12:12 PM
pulisher
09:13 AM

What drives Galectin Therapeutics Inc. stock priceRapidly growing investment returns - jammulinksnews.com

09:13 AM
pulisher
Jul 22, 2025

What analysts say about Galectin Therapeutics Inc. stockAccelerated wealth building - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Galectin Therapeutics Inc. a good long term investmentAccelerated wealth building - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat

Jul 22, 2025
pulisher
Jul 18, 2025

Director’s Bold Move: Major Stock Purchase at Galectin Therapeutics! - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Freeman buys Galectin therapeutics (GALT) stock worth $14,495 - Investing.com Australia

Jul 18, 2025
pulisher
Jul 18, 2025

Freeman buys Galectin therapeutics (GALT) stock worth $14,495 By Investing.com - Investing.com Nigeria

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Galectin Therapeutics Inc. stock price move sharplyMarket Ready Callouts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Galectin Therapeutics Inc. stock attracts strong analyst attentionLow Volatility High Yield Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Did Galectin Therapeutics (GALT) Soar 14.04%? - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

How Galectin Therapeutics Inc. stock performs during market volatilityFree Discussion Group - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

Galectin Therapeutics (NASDAQ:GALT) Share Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat

Jul 13, 2025
pulisher
Jul 10, 2025

Galectin Therapeutics announces new $10 million credit line from Richard Uihlein - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Galectin Therapeutics Secures $10M Credit Line for Growth - The Globe and Mail

Jul 10, 2025
pulisher
Jul 10, 2025

Galectin Therapeutics secures $10 million credit line from board chairman By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 09, 2025

Galectin Therapeutics secures $10 million credit line from board chairman - Investing.com Australia

Jul 09, 2025
pulisher
Jul 09, 2025

Galectin Therapeutics Inc. announced that it expects to receive $10 million in funding - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

Galectin Therapeutics Secures Additional $10 million Credit Line - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

ALVO 6-K: Alvotech discloses Ivers-Lee Group acquisition | GALT SEC FilingForm 8-K - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 - TradingView

Jul 09, 2025
pulisher
Jul 09, 2025

Board Chairman Injects $10M Into Galectin's MASH Treatment Program: Extended Funding Through 2026 - Stock Titan

Jul 09, 2025
pulisher
Jul 04, 2025

Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat

Jul 04, 2025
pulisher
Jul 01, 2025

Galectin Therapeutics Inc.'s (NASDAQ:GALT) stock price dropped 13% last week; individual investors would not be happy - simplywall.st

Jul 01, 2025
pulisher
Jun 24, 2025

Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Jun 24, 2025
pulisher
Jun 22, 2025

What is HC Wainwright's Estimate for GALT Q2 Earnings? - MarketBeat

Jun 22, 2025
pulisher
Jun 20, 2025

Equities Analysts Issue Forecasts for GALT Q2 Earnings - Defense World

Jun 20, 2025
pulisher
Jun 19, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Holdings Lifted by Wealth Enhancement Advisory Services LLC - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Galectin Therapeutics (NASDAQ:GALT) Now Covered by Analysts at HC Wainwright - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

Galectin Therapeutics Soars 22% Amid Technical Puzzles and Retail Surge - AInvest

Jun 18, 2025
pulisher
Jun 17, 2025

Galectin Therapeutics stock rating initiated at buy by H.C. Wainwright - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Analyst Forecast For Galectin Therapeutics Inc (NASDAQ: GALT) - Stocksregister

Jun 17, 2025
pulisher
Jun 17, 2025

Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainw - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

HC Wainwright Initiates Coverage on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

HC Wainwright & Co. Initiates Coverage with Buy Rating on GALT | - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainwright | GALT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

Transcript : Galectin Therapeutics Inc.Special Call - MarketScreener

Jun 16, 2025

Galectin Therapeutics Inc Stock (GALT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Cap:     |  Volume (24h):